Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics CEO Says Clinical Sequencing Will Require 'Redefinition' of Data Delivered

Premium

By Julia Karow

Human whole-genome sequencing
for the clinical market will require a new type of product that delivers less data than is currently provided for the research market, according to Complete Genomics CEO Cliff Reid.

Reid also said that a lack of data analysis and storage capabilities is currently the greatest barrier preventing the company from securing large deals with translational medicine institutions.

During a conference call to discuss the company's third-quarter earnings this week, Reid said the company has been delivering "a huge amount of data" to its research customers, enabling them to mine the data according to their research goals.

The clinical market, on the other hand, will require a "fundamental redefinition of the delivered product," he said. Instead of providing large datasets, the company will need to reduce the data "all the way down to clinical reports that are simply actionable answers to clinical questions."

Reid said that the biggest obstacle for securing large contracts from translational medicine organizations — similar to the one it recently signed with the Inova Translational Medicine Institute (CSN 8/9/2011) — is not the price of its whole-genome sequencing service, which is currently on the order of $5,000 per genome or less, but in the lack of data analysis and storage capabilities at customer sites.

While genome sequence data is often "discarded" in the research space after the results are published, translational researchers "sequence patients and keep the data associated with the patient for multi-year longitudinal studies, and go back and mine the data over and over again," Reid said.

Unlike genome centers, which have their own data analysis capabilities, translational research centers "have to work with partners" to analyze and store the data, he said. "We see infrastructure barriers, not price or a desire to do genome sequencing on the cheap."

Still, Complete hopes that much of its future business will come from customers based in translational medicine, rather than basic research. "There are few basic researchers who have 10,000 samples," Reid said. "There are a lot of hospital networks with 10,000 patients."


Have topics you'd like to see covered in Clinical Sequencing News? Contact the editor at jkarow [at] genomeweb [.] com.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.